Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

8.38USD
26 Jun 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.38
Open
--
Day's High
--
Day's Low
--
Volume
175
Avg. Vol
1,312,414
52-wk High
$11.00
52-wk Low
$5.83

Latest Key Developments (Source: Significant Developments)

Inovio begins phase 3 clinical trial of VGX-3100
Thursday, 8 Jun 2017 06:00am EDT 

June 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio begins phase 3 clinical trial of VGX-3100 for the treatment of HPV-related cervical pre-cancer.Plans to immediately begin recruiting patients for phase 3 trial.Pivotal data from program will support potential licensure of VGX-3100 as first immunotherapy for this disease​.  Full Article

Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor
Thursday, 1 Jun 2017 08:00am EDT 

June 1 (Reuters) - Inovio Pharmaceuticals Inc :Inovio announces clinical trial collaboration to evaluate a novel t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor.Inovio Pharmaceuticals Inc - ‍clinical collaboration with Genentech, a member of Roche Group, for advanced bladder cancer​.Inovio Pharmaceuticals Inc - ‍multi-center open-label trial will be managed by Inovio, and Genentech will supply Atezolizumab​.Inovio Pharmaceuticals Inc - trial ‍is anticipated to start in 2017 and designed to evaluate safety, immune response and clinical efficacy.Inovio Pharmaceuticals- ‍majority of patients to be enrolled in trial to have previously received, failed to demonstrate meaningful response to checkpoint inhibitor alone​.  Full Article

Inovio's HIV vaccine produces nearly 100 pct immune response rates in clinical study
Wednesday, 24 May 2017 08:00am EDT 

May 24 (Reuters) - Inovio Pharmaceuticals Inc :Inovio HIV vaccine elicits nearly 100% immune response rates in a clinical study.Inovio Pharmaceuticals Inc - amongst evaluated participants receiving PENNVAX-GP and IL-12 via im vaccination, 27 of 27 demonstrated a cellular response.  Full Article

Inovio Pharmaceuticals reports Q1 revenue $10.4 million
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 first quarter financial results.Q1 loss per share $0.31.Q1 revenue $10.4 million versus $8.1 million.Q1 revenue view $5.8 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

Inovio pharmaceuticals says AstraZeneca's MedImmune will start new clinical trial
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Inovio Pharmaceuticals Inc :Inovio provides update on MedImmune launch of combination trial for hpv-associated head & neck cancer.Inovio Pharmaceuticals-AstrazZneca's medimmune will start a new clinical trial investigating combination of medi0457.Inovio Pharmaceuticals-new clinical trial will investigate combination of medi0457 and durvalumab, an investigational pd-l1 checkpoint inhibitor.  Full Article

Regeneron and Inovio enter immuno-oncology clinical study agreement
Monday, 8 May 2017 07:30am EDT 

May 8 (Reuters) - Inovio Pharmaceuticals Inc : :Regeneron and Inovio enter immuno-oncology clinical study agreement for glioblastoma combination therapy.Regeneron Pharmaceuticals Inc - study will be conducted by inovio in patients with newly-diagnosed glioblastoma multiforme.Regeneron-Study to evaluate co's pd-1 inhibitor, regn2810, with Inovio's ino-5401 t cell activating immunotherapy encoding multiple antigens and ino-9012.Regeneron - trial will be solely conducted and funded by inovio, based upon a mutually agreed upon study design, and regeneron will supply regn2810.Regeneron Pharmaceuticals Inc - Inovio and regeneron will jointly conduct immunological analyses in support of study.Regeneron Pharmaceuticals Inc - Regeneron, in collaboration with Sanofi, is developing regn2810 both alone and in combination with other therapies.  Full Article

Inovio initiates Phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers
Monday, 24 Apr 2017 08:00am EDT 

April 24 (Reuters) - Inovio Pharmaceuticals Inc ::Inovio initiates phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers.Plans to initiate a phase 3 study of VGX-3100 as a treatment for high grade cervical dysplasia in 2017.  Full Article

Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial
Tuesday, 11 Apr 2017 09:00am EDT 

Inovio Pharmaceuticals Inc : Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial . Inovio Pharma - results across both stages of trial showed that 95 pct of evaluable subjects generated an Ebola-specific antibody immune response . Inovio Pharmaceuticals Inc - Inovio's Ebola vaccine was well-tolerated with a favorable safety profile compared to viral vector-based Ebola vaccines .Inovio Pharmaceuticals Inc - plan to meet with regulators this year regarding a path forward for licensure of Ebola product.  Full Article

Inovio Pharma wins $6.95 mln NIH grant
Thursday, 30 Mar 2017 08:00am EDT 

Inovio Pharmaceuticals Inc : Inovio pharma-co's academic, industry collaborators received multi-year $6.95 million grant from nih's national institute of allergy & infectious diseases .Inovio-Grant to develop single or combination therapy using co's pennvax-gp with goal of attaining long-term hiv remission in absence of antiviral drugs.  Full Article

Inovio's zika vaccine generates robust immune responses in first human study
Wednesday, 21 Dec 2016 08:00am EST 

Inovio Pharmaceuticals Inc : Inovio's zika vaccine generates robust immune responses in first human study .Inovio Pharma- vaccine was well tolerated, no significant safety concerns noted in any of 40 subjects out to 14 weeks from initiation of dosing.  Full Article

More From Around the Web

BRIEF-Inovio begins phase 3 clinical trial of VGX-3100

* Inovio begins phase 3 clinical trial of VGX-3100 for the treatment of HPV-related cervical pre-cancer